Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2016
Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2010
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2010
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2010
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2010
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PL Developments Gains FDA Nod for Omeprazole ANDA, Completes Debt Refinancing
Details : The FDA has approved PLD's Omeprazole Magnesium Tablet, a generic equivalent to Prilosec OTC for the treatment in adults of duodenal ulcer and gastric ulcer.
Product Name : Prilosec-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Talicia® Launched in the United Arab Emirates
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Product Name : Talicia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Product Name : Talicia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Pharma Metric Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Omeprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Pharma Metric Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : AnHeart Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : AnHeart Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable